Merck & Co., Inc., Rahway, N.J., USA TL1A Antibody Met Phase 2b Endpoints in HS

Merck reported tulisokibart met the HiSCR50 primary endpoint in Phase 2b HS, with 72% (Q2W) and 64% (Q4W) vs 35% placebo at week 16, and plans to advance to Phase 3. Safety was comparable to placebo; no serious or opportunistic infections were observed.Material DetailsContext by AI AnalystThis is m…